Results 91 to 100 of about 11,492 (193)

MAFLD - a new approach to fatty liver disease [PDF]

Fatty liver disease associated with metabolic dysfunction (MAFLD) is a term introduced in 2020 to refer to fatty liver disease associated with systemic metabolic dysregulation.
Grzybek, Monika, Szostak, Barbara, Łozowski, Borys, Kasprzak, Małgorzata, Brzuszkiewcz-Łozowska, Kinga, Kasprzak, Anna, Tyszkiewicz, Krzysztof, Kułaga, Monika, Wielgosz-Biała, Sylwia, Mazur-Lesińska, Diana, Wilczyńska, Barbara   +10 more
core   +3 more sources

Protective Effect of Modified Suanmei-Tang on Metabolic-Associated Fatty Liver Disease: An Integrated Strategy of Network Pharmacology, Metabolomics, and Transcriptomics

Drug Design, Development and Therapy
Chao Wang,1,* Mei Zhao,2,* Yuanyuan Yue,3 Chao Hu,2 Chunqiu Zhou,2 Zhongyi Zhang,2 Yunliang He,4 Yaqi Luo,4 Tao Shen,2 Sijie Dang,4 Yang Yang,4 Yong Zhang2,4 1Traditional Chinese Medicine Department, Qitai Hospital of the Sixth Division, Xinjiang,
Wang C, Zhao M, Yue Y, Hu C, Zhou C, Zhang Z, He Y, Luo Y, Shen T, Dang S, Yang Y, Zhang Y   +11 more
doaj  

Unlocking the Hepatoprotective Potential of Urolithin A in High‐Fat Diet‐Induced MASLD: Integrated Role of Oxidative Stress, Inflammation, FXR/PPAR‐α, and Fibrotic Pathway

Cell Biochemistry and Function, Volume 44, Issue 9, September 2026.
ABSTRACT “Metabolic dysfunction–associated steatotic liver disease” (MASLD) is marked by hepatic steatosis, oxidative stress, inflammation, and fibrosis. Urolithin A (Uro A), a metabolite of ellagitannins, exhibits anti‐inflammatory, antioxidant, and metabolic regulatory activities.
Hamad Alsaykhan, Amany Mohamed Shalaby, Walaa Arafa Keshk, Shahd Saad El‐dien Kamel, Sulaiman Mohammed Alnasser, Mohammed Alorini, Fatima A. Jaber, Mohamed Ali Alabiad, Amr Mohamed Younes, Hanim Magdy Abdelnour   +9 more
wiley   +1 more source

The coexistence of MAFLD increases fibrosis burden in patients with chronic hepatitis B

Scientific Reports
Despite the increasing recognition of metabolic dysfunction-associated fatty liver disease (MAFLD) and Chronic Hepatitis B (CHB), their interplay on liver fibrosis remains insufficiently elucidated.
Alaa Mohamed Mostafa, Yasser Fouad, Nadia Abdelaaty Abdelkader, Omar Magdy, Nehal Refaat Raouf, Mohammed Eslam   +5 more
doaj   +1 more source

A pitfall in the evaluation of Sampson‐estimated small dense LDL cholesterol in metabolic disorders: Is it equivalent to directly measured sdLDL‐C?

Journal of Diabetes Investigation, EarlyView.
Tsutomu Hirano
wiley   +1 more source

Global Research Landscape on Leptin Resistance and Obesity‐Related Metabolic Dysfunction: Trends, Networks and Visualisation Analysis (1995–2025)

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Analysis of 2162 Scopus publications showed that research on leptin resistance and obesity‐related metabolic dysfunction expanded markedly from 1995 to 2025, peaking in 2014 before stabilising. The field broadened towards inflammatory, cardiometabolic and mechanistic topics, while international collaboration remained concentrated among high‐output ...
Sa'ed. H. Zyoud
wiley   +1 more source

Effect of Intermittent Fasting on Weight Loss in Overweight and Obese Adults: A Systematic Review of Clinical Trials

Food Science &Nutrition, Volume 14, Issue 9, September 2026.
This systematic review screened 2307 records identified through PubMed, Cochrane Library, Google Scholar, and ScienceDirect, following PRISMA 2020 criteria. The search yielded 26 eligible clinical trials (24 RCTs, 2 non‐randomized studies) on intermittent fasting (TRE 16:8/20:4/14:10/18:6, alternate‐day fasting, and 5:2 fasting) for weight loss in ...
Hafiz Muhammad Irfan Manzoor, Muhammad Tauseef Sultan, Aneela Hameed, Ahmad Mujtaba Noman, Mahnoor Khalid, Maheen Kazmi, Aiman Sohail, Mohamed Fawzy Ramadan, Eliasse Zongo, Muhammad Abdul Rahim, Fahad Al‐Asmari   +10 more
wiley   +1 more source

Funnel plot for MAFLD in persons with T2D.

Metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes (T2D) are interconnected metabolic disorders with significant health implications.
Precious Adade Duodu (8566200), Samuel Akyirem (10153436), Emmanuel Ekpor (14670449)   +2 more
core   +1 more source

Curcumin Analog J7 Attenuates Liver Fibrosis and Metabolic Dysregulation in a Rat Model of Type 2 Diabetes via Modulation of TGF-β/Smad and NF-κB/BCL-2/BAX Pathways

Drug Design, Development and Therapy
Jun Ma,1 Wei Chen,2 Deep K Vaishnani,3 Congying Wang,2 Shuman Xue,2 Qiuqin Yang,4 Yuheng Tong,4 Ningjia Lei,5 Zhichao Zhao,6 Furong Ying7 1Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000 ...
Ma J, Chen W, Vaishnani DK, Wang C, Xue S, Yang Q, Tong Y, Lei N, Zhao Z, Ying F   +9 more
doaj  

European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) steatotic liver disease special interest group position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction‐associated steatotic liver disease

Journal of Pediatric Gastroenterology and Nutrition, Volume 83, Issue 3, Page 555-576, September 2026.
Abstract Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common reason for elevated liver enzymes in children in Europe, affecting more than 5% of all children. Since the last iteration of this position paper, there have been substantial advances in our understanding of the disease.
Jake P. Mann, Sander Lefere, Maarten Buytaert, Anna Alisi, Cigdem Arikan, Jernej Brecelj, Rachel M. Brown, Irene Degrassi, Giulia Fiore, Emer Fitzpatrick, Sven Francque, Christian A. Hudert, Wojciech Janczyk, Lauren Johansen, Bart G. Koot, Anastasia Konidari, Eberhard Lurz, Claudia Mandato, Maria Mercadal‐Hally, Hadar Moran‐Lev, Antonella Mosca, Giusy Ranucci, Maria Rogalidou, Penelope C. Rose, Piotr Socha, Pietro Vajro, Elvira Verduci, Anita C. E. Vreugdenhil, Natalia Zavhorodnia, Aglaia Zellos, Ruth De Bruyne   +30 more
wiley   +1 more source